CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Atezolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03976518
NCT03976518Phase 2Completed
CompareCT.gov

Phase II, Open-label Study of Atezolizumab in a Cohort of Pretreated, Advanced Non-small Cell Lung Cancer (NSCLC) Patients With Rare Histological Subtypes (CHANCE Trial).

Gruppo Oncologico Italiano di Ricerca Clinica·interventional·Posted Jun 6, 2019·Updated Mar 1, 2024

In Brief

A Phase 2 clinical trial evaluating Atezolizumab for Non-Small Cell Lung Cancer. Completed, enrolled 43 participants across 10 sites.

Detailed Summary

This study is aimed to explore the antitumor activity and the safety profile of atezolizumab in pretreated advanced NSCLC patients with rare histological subtypes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesItaly
CollaboratorsAOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, IQVIA Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 6, 2019
Enrollment StartMay 7, 2019
Primary CompletionFeb 12, 2024
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 7.1 years ago

Interventions

Atezolizumabdrug

Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).